Efocipegtrutide

Investigated uses

• Obesity and metabolic or fibrotic liver disease in clinical development.

Mechanism and hypotheses

• Efocipegtrutide is designed as a long-acting agonist of GLP-1, GIP and glucagon receptors.

Human evidence

• A randomized first-in-human study evaluated single ascending subcutaneous doses in 41 adults with obesity. Limitations: Early-phase exposure does not establish efficacy, long-term safety or an appropriate general-use dose.

Safety highlights

• The adverse-event profile remains insufficiently characterized outside controlled clinical development.
• Long-term and uncommon risks are not established because no approved label or postmarketing record exists.

Regulatory context

Investigational; no FDA-approved efocipegtrutide product.